Hubbry Logo
Pulmonary function testingPulmonary function testingMain
Open search
Pulmonary function testing
Community hub
Pulmonary function testing
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Pulmonary function testing
Pulmonary function testing
Pulmonary function testing
View on Wikipedia
from Wikipedia
Pulmonary function testing
Plethysmograph "body box"
MeSHD012129
OPS-301 code1-71
MedlinePlus003853
TLCTotal lung capacity: the volume in the lungs at maximal inflation, the sum of VC and RV.
TVTidal volume: that volume of air moved into or out of the lungs in 1 breath (TV indicates a subdivision of the lung; when tidal volume is precisely measured, as in gas exchange calculation, the symbol TV or VT is used.)
RVResidual volume: the volume of air remaining in the lungs after a maximal exhalation
ERVExpiratory reserve volume: the maximal volume of air that can be exhaled from the end-expiratory position
IRVInspiratory reserve volume: the maximal volume that can be inhaled from the end-inspiratory level
ICInspiratory capacity: the sum of IRV and TV
IVCInspiratory vital capacity: the maximum volume of air inhaled from the point of maximum expiration
VCVital capacity: the volume of air breathed out after the deepest inhalation.
VTTidal volume: that volume of air moved into or out of the lungs during quiet breathing (VT indicates a subdivision of the lung; when tidal volume is precisely measured, as in gas exchange calculation, the symbol TV or VT is used.)
FRCFunctional residual capacity: the volume in the lungs at the end-expiratory position
RV/TLC%Residual volume expressed as percent of TLC
VAAlveolar gas volume
VLActual volume of the lung including the volume of the conducting airway.
FVCForced vital capacity: the determination of the vital capacity from a maximally forced expiratory effort
FEVtForced expiratory volume (time): a generic term indicating the volume of air exhaled under forced conditions in the first t seconds
FEV1Volume that has been exhaled at the end of the first second of forced expiration
FEFxForced expiratory flow related to some portion of the FVC curve; modifiers refer to amount of FVC already exhaled
FEFmaxThe maximum instantaneous flow achieved during a FVC maneuver
FIFForced inspiratory flow: (Specific measurement of the forced inspiratory curve is denoted by nomenclature analogous to that for the forced expiratory curve. For example, maximum inspiratory flow is denoted FIFmax. Unless otherwise specified, volume qualifiers indicate the volume inspired from RV at the point of measurement.)
PEFPeak expiratory flow: The highest forced expiratory flow measured with a peak flow meter
MVVMaximal voluntary ventilation: volume of air expired in a specified period during repetitive maximal effort

Pulmonary function testing (PFT) is a complete evaluation of the respiratory system including patient history, physical examinations, and tests of pulmonary function. The primary purpose of pulmonary function testing is to identify the severity of pulmonary impairment.[1] Pulmonary function testing has diagnostic and therapeutic roles and helps clinicians answer some general questions about patients with lung disease. PFTs are normally performed by a pulmonary function technologist, respiratory therapist, respiratory physiologist, physiotherapist, pulmonologist, or general practitioner.

Indications

[edit]

Pulmonary function testing is a diagnostic and management tool used for a variety of reasons, such as:

  • Diagnose lung disease.
  • Monitor the effect of chronic diseases like asthma, chronic obstructive lung disease, or cystic fibrosis.
  • Detect early changes in lung function.
  • Identify narrowing in the airways.
  • Evaluate airway bronchodilator reactivity.
  • Show if environmental factors have harmed the lungs
  • Preoperative testing[2]

Neuromuscular disorders

[edit]

Pulmonary function testing in patients with neuromuscular disorders helps to evaluate the respiratory status of patients at the time of diagnosis, monitor their progress and course, evaluate them for possible surgery, and gives an overall idea of the prognosis.[3]

Duchenne muscular dystrophy is associated with gradual loss of muscle function over time. Involvement of respiratory muscles results in poor ability to cough and decreased ability to breathe well and leads to collapse of part or all of the lung leading to impaired gas exchange and an overall insufficiency in lung strength.[4]

Tests

[edit]

Spirometry

[edit]
Main article: Spirometry
Spirometry

Spirometry includes tests of pulmonary mechanics – measurements of FVC, FEV1, FEF values, forced inspiratory flow rates (FIFs), and MVV. Measuring pulmonary mechanics assesses the ability of the lungs to move huge volumes of air quickly through the airways to identify airway obstruction.[citation needed]

The measurements taken by the spirometry device are used to generate a pneumotachograph that can help to assess lung conditions such as: asthma, pulmonary fibrosis, cystic fibrosis, and chronic obstructive pulmonary disease. Physicians may also use the test results to diagnose bronchial hyperresponsiveness to exercise, cold air, or pharmaceutical agents.[5]

Helium dilution

[edit]
Main article: Helium dilution technique

The helium dilution technique for measuring lung volumes uses a closed, rebreathing circuit.[6] This technique is based on the assumptions that a known volume and concentration of helium in air begin in the closed spirometer, that the patient has no helium in their lungs, and that an equilibration of helium can occur between the spirometer and the lungs.[citation needed]

Nitrogen washout

[edit]
Main article: Nitrogen washout

The nitrogen washout technique uses a non-rebreathing open circuit. The technique is based on the assumptions that the nitrogen concentration in the lungs is 78% and in equilibrium with the atmosphere, that the patient inhales 100% oxygen and that the oxygen replaces all of the nitrogen in the lungs.[7]

Plethysmography

[edit]
Main articles: Plethysmograph and Lung volumes

The plethysmography technique applies Boyle's law and uses measurements of volume and pressure changes to determine total lung volume, assuming temperature is constant.[8]

There are four lung volumes and four lung capacities. A lung's capacity consists of two or more lung volumes. The lung volumes are tidal volume (VT), inspiratory reserve volume (IRV), expiratory reserve volume (ERV), and residual volume (RV). The four lung capacities are total lung capacity (TLC), inspiratory capacity (IC), functional residual capacity (FRC) and vital capacity (VC).

Maximal respiratory pressures

[edit]
Main article: Respiratory pressure meter

Measurement of maximal inspiratory and expiratory pressures is indicated whenever there is an unexplained decrease in vital capacity or respiratory muscle weakness is suspected clinically. Maximal inspiratory pressure (MIP) is the maximal pressure that can be produced by the patient trying to inhale through a blocked mouthpiece. Maximal expiratory pressure (MEP) is the maximal pressure measured during forced expiration (with cheeks bulging) through a blocked mouthpiece after a full inhalation. Repeated measurements of MIP and MEP are useful in following the course of patients with neuromuscular disorders.[citation needed]

Diffusing capacity

[edit]
Main article: Diffusing capacity

Measurement of the single-breath diffusing capacity for carbon monoxide (DLCO) is a fast and safe tool in the evaluation of both restrictive and obstructive lung disease.[citation needed]

Bronchodilator responsiveness

[edit]

When a patient has an obstructive defect, a bronchodilator test is given to evaluate if airway constriction is reversible with a short acting beta-agonist. This is defined as an increase of ≥12% and ≥200 mL in the FEV1 or FVC.[9]

Oxygen desaturation during exercise

[edit]

The six-minute walk test is a good index of physical function and therapeutic response in patients with a chronic lung disease, such as COPD or idiopathic pulmonary fibrosis.[10][11][12]

Arterial blood gases

[edit]

Arterial blood gases (ABGs) are a helpful measurement in pulmonary function testing in selected patients. The primary role of measuring ABGs in individuals that are healthy and stable is to confirm hypoventilation when it is suspected on the basis of medical history, such as respiratory muscle weakness or advanced COPD.[citation needed]

ABGs also provide a more detailed assessment of the severity of hypoxemia in patients who have low normal oxyhemoglobin saturation.[citation needed]

Risks

[edit]

Pulmonary function testing is a safe procedure; however, there is cause for concern regarding untoward reactions and the value of the test data should be weighed against potential hazards. Some complications include dizziness, shortness of breath, coughing, pneumothorax, and inducing an asthma attack.[13][14]

Contraindications

[edit]

There are some indications against a pulmonary function test being done. These include a recent heart attack, stroke, head injury, an aneurysm, or confusion.[15]

Technique

[edit]

Preparation

[edit]

Subjects have measurements of height and weight taken before spirometry to determine what their predicted values should be. Additionally, a history of smoking, recent illness, and medications is taken.[citation needed]

Quality control

[edit]

In order for the forced vital capacity to be considered accurate it has to be conducted three times where the peak is sharp in the flow-volume curve and the exhalation time is longer than 6 seconds.

Repeatability of the PFT is determined by comparing the values of forced vital capacity (FVC) and forced expiratory volume at 1 second (FEV1). The difference between the highest values of two FVCs need to be within 5% or 150 mL. When the FVC is less than 1.0 L, the difference between the highest two values must be within 100 mL. Lastly, the difference between the two highest values of FEV1 should also be within 150 mL. The highest FVC and FEV1 may be used from each different test. Until the results of three tests meet the criteria of reproducibility, the test can be repeated up to eight times. If it is still not possible to get accurate results, the best three tests are used.[16]

Clinical significance

[edit]

Changes in lung volumes and capacities from normal are generally consistent with the pattern of lung impairment.

Spirometry is required for a diagnosis of COPD.[17]

Interpretation of tests

[edit]
Classification of COPD based on spirometry[18]
Severity FEV1 % predicted
Mild (GOLD 1) ≥80
Moderate (GOLD 2) 50–79
Severe (GOLD 3) 30–49
Very severe (GOLD 4) <30
See also: Spirometer § History - Interpreting Spirometry

Professional societies such as the American Thoracic Society and the European Respiratory Society have published guidelines regarding the conduct and interpretation of pulmonary function testing to ensure standardization and uniformity in performance of tests. The interpretation of tests depends on comparing the patients values to published normals from previous studies. Deviation from guidelines can result in false-positive or false negative test results, even though only a small minority of pulmonary function laboratories followed published guidelines for spirometry, lung volumes and diffusing capacity in 2012.[19]

COPD

[edit]

The Global Initiative for Chronic Obstructive Lung Disease provides guidelines for the diagnosis, severity, and management of COPD.[20] To determine obstruction in a patient's lungs, the post-bronchodilator FEV1/FVC needs to be <0.7.[17] Then, the FEV1 percentage of predicted result is used to determine the degree of obstruction where the lower the percent the worse the obstruction.[18]

Maximum respiratory pressures

[edit]

Several calculations are needed for what a normal maximum inspiratory (MIP) and expiratory pressure (MEP) is. For males this found by:

and

To find the lower limit of what is acceptable in males the equations are:

and

For females, the equations are slightly different. For the normal values this is used:

and

For find the lower limit of what it should be without impairment this form of the equations is used:

and

where

  • = maximum inspiratory pressure in cmH20
  • = maximum expiratory pressure in cmH20
  • = maximum inspiratory pressure lower limit of normal in cmH20
  • = maximum expiratory pressure lower limit of normal in cmH20
  • = the patient's age in years[21]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Pulmonary function testing

View on Grokipedia
from Grokipedia
Pulmonary function testing (PFT), also referred to as lung function testing, comprises a group of noninvasive diagnostic procedures that assess the respiratory system's function by measuring key parameters such as lung volumes, airflow rates, capacities, and efficiency. These tests provide quantitative data on how effectively the lungs inhale, exhale, and transfer gases like oxygen and , helping to identify abnormalities in lung mechanics and performance. The primary purposes of PFT include diagnosing respiratory disorders, monitoring disease progression, evaluating treatment responses, and assessing surgical risks or occupational exposures. They are particularly valuable for detecting obstructive lung diseases, such as and (COPD), where airflow is impeded, or restrictive conditions, like , where lung expansion is limited. Results are interpreted by comparing measured values to predicted norms adjusted for factors such as age, sex, and height, with recent guidelines from organizations like the American Thoracic Society recommending race-neutral reference equations over ethnicity-specific adjustments, and abnormalities indicating potential when integrated with clinical history and . Common types of PFTs encompass , which evaluates forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and the to differentiate obstructive from restrictive patterns; lung volume testing via body plethysmography or gas dilution methods to determine total lung capacity (TLC), residual volume (RV), and (FRC); and diffusion capacity (DLCO) studies that measure the s' ability to transfer gas to the bloodstream using as a proxy. Additional tests may include bronchoprovocation challenges to assess airway hyperresponsiveness or exercise-based evaluations like the six-minute walk test for functional capacity. PFTs are generally safe and performed in outpatient settings by trained respiratory therapists, lasting 15 to 45 minutes, though they may cause temporary discomfort such as , coughing, or in susceptible individuals. Preparation typically involves avoiding heavy meals, , smoking, and certain medications, with contraindications including recent or . Standardized guidelines from organizations like the American Thoracic Society and European Respiratory Society ensure consistent interpretation and quality control.

Overview

Definition and Purpose

Pulmonary function testing (PFT) comprises a group of noninvasive diagnostic procedures that assess mechanics and by measuring parameters such as lung volumes and capacities, airflow rates, diffusion capacity for gases, and respiratory muscle function. These tests provide objective on how effectively the lungs perform their primary roles of ventilation and oxygenation, enabling clinicians to quantify respiratory in various physiological states. The core purposes of PFT are to aid in the of impairments, evaluate the severity of existing conditions, monitor changes in function over time or in response to therapeutic interventions, assess surgical risk in patients undergoing procedures that may affect respiration, and screen for potential hazards in occupational settings. By establishing baseline measurements and tracking deviations from predicted norms—adjusted for factors like age, sex, and height using race-neutral reference equations—PFT helps guide clinical decision-making and predict outcomes in respiratory care. PFT distinguishes between static and dynamic assessments: static tests evaluate lung volumes and capacities under relaxed conditions, independent of speed, whereas dynamic tests measure and resistance during effort-dependent maneuvers, such as forced . At a high level, test results can indicate obstructive patterns, marked by limitations in , or restrictive patterns, characterized by diminished lung volumes, providing foundational insights into the type of ventilatory dysfunction present. PFT laboratories are equipped with standardized apparatus, including volume- or flow-sensing spirometers for airflow evaluation, whole-body plethysmographs (body boxes) for precise lung volume measurements via , and gas analyzers for diffusion studies, all calibrated daily and operated by certified technicians in environments adhering to infection control protocols to ensure measurement reliability and .

Historical Development

The origins of pulmonary function testing (PFT) trace back to the mid-19th century, when English physician John Hutchinson developed the first practical in 1846 to measure , the maximum volume of air that could be exhaled after a full . Hutchinson's water-filled , a large submerged in a tank, allowed for quantitative assessment of lung volumes in over 2,000 healthy individuals and patients, establishing as a key indicator of respiratory health influenced by factors like age, height, and body weight. This device marked the beginning of systematic PFT, shifting from qualitative observations to precise volumetric measurements, though early were cumbersome and limited to static lung volumes. In the , PFT expanded with innovative techniques for measuring total lung volumes and . The helium dilution method, introduced in 1949 by Meneely and Kaltreider, enabled accurate determination of by having patients rebreathe a helium-oxygen mixture, allowing inert gas dilution to estimate alveolar volume without requiring full . Following , diffusing capacity tests gained prominence, building on Marie Krogh's 1915 carbon monoxide uptake concept but refined into the single-breath diffusing capacity for (DLCO) in the 1950s, which quantified the lung's ability to transfer gases across the alveolar-capillary membrane. Body plethysmography, pioneered by DuBois and colleagues in 1956, provided a non-invasive way to measure thoracic gas volume and using in a sealed chamber, overcoming limitations of dilution methods in obstructive diseases. Standardization efforts accelerated in the late to ensure reproducibility across labs. The American Thoracic Society (ATS) issued its first comprehensive guidelines for in 1979, emphasizing standardized maneuvers, equipment calibration, and acceptability criteria, which were later harmonized with the European Respiratory Society (ERS). These were updated in joint ATS/ERS statements, including the 2005 standards for that refined reference values and quality control, the 2019 update to standardization, the 2017 standards for single-breath DLCO uptake in the , and the 2022 technical standard on interpretive strategies for routine lung function tests. In 2023, the ATS issued a statement recommending race-neutral reference equations for PFT interpretation to address historical biases in ethnicity-based adjustments. Technological advancements paralleled this, with the transition from wet spirometers—prone to spillage and temperature errors—to dry rolling-seal or turbine-based devices in the mid-, improving portability and accuracy. By the 1980s and 1990s, integration of microprocessor-based computer software enabled real-time data acquisition, automated curve analysis, and expert systems like PUFF for interpretive reporting, enhancing diagnostic efficiency. In the since the , PFT incorporated dynamic assessments such as cardiopulmonary exercise testing, standardized by ATS/ACCP guidelines in 1999 to evaluate integrated cardiorespiratory function under stress. Exhaled measurement emerged as a non-invasive marker of airway , with fractional exhaled nitric oxide (FeNO) techniques validated in the early for monitoring. These developments, supported by ongoing ATS/ERS updates, have solidified PFT as a cornerstone of respiratory diagnostics.

Indications

Respiratory Diseases

Pulmonary function testing (PFT) is indicated in obstructive lung diseases such as and (COPD) to diagnose airflow limitation and differentiate between reversible and irreversible obstruction. In , PFT assesses responsiveness, with pre- and post- spirometry helping identify reversible airway obstruction typically showing a significant increase in forced expiratory volume in one second (FEV1) after administration. For COPD, PFT confirms irreversible airflow obstruction, characterized by a reduced FEV1/forced (FVC) ratio that persists post-, aiding in severity staging and monitoring disease progression. In restrictive lung diseases, PFT evaluates reduced lung volumes to support and assess disease extent. For (IPF), PFT demonstrates a restrictive pattern with decreased total capacity (TLC) and FVC, often accompanied by impaired , which informs and treatment decisions as per ATS/ERS/JRS/ALAT guidelines. Similarly, in , PFT detects restrictive ventilatory defects due to parenchymal involvement, with reduced lung volumes correlating to disease severity and guiding therapeutic interventions. PFT serves additional roles in other respiratory conditions, including preoperative risk stratification for lung resection, where baseline measurements predict postoperative function and surgical tolerance. In , PFT monitors exacerbations and tracks longitudinal lung function decline, with providing key metrics for timely intervention. For occupational pneumoconioses, such as or , PFT assesses dust-induced restrictive or mixed defects in exposed workers to evaluate impairment and support compensation claims. Spirometry is recommended in primary care for case-finding in adults over 40 years with a significant history and respiratory symptoms, such as , production, or unexplained dyspnea, to detect early obstructive diseases like COPD.

Neuromuscular and Other Disorders

Pulmonary function testing (PFT) plays a crucial role in evaluating respiratory involvement in neuromuscular disorders, where primary is absent but impairs ventilation mechanics. In these conditions, PFT helps detect early respiratory compromise, guide ventilatory support decisions, and monitor disease progression. In (ALS), PFT is indicated to assess diaphragmatic weakness, often through measurements of maximal inspiratory pressure (), which can identify reductions below -30 cmH2O signaling significant impairment. Supine spirometry further enhances detection by revealing a greater than 20-30% drop in forced (FVC) compared to upright position, reflecting diaphragm dysfunction. Similarly, in , PFT evaluates respiratory muscle strength during exacerbations, showing a restrictive pattern due to inspiratory and expiratory weakness, with maximal pressures aiding in identifying the need for ventilatory intervention. For , PFT serves as a screening tool for sleep-disordered , where reduced FVC and oxygen desaturation during (SpO2 ≤ 88% for ≥5 minutes) predict and guide initiation. Cardiovascular conditions also warrant PFT to quantify secondary effects on breathing. In , testing evaluates abnormalities, with reduced (DLCO) commonly observed, helping differentiate vascular from parenchymal issues. For , PFT assesses restrictive deficits and impaired gas transfer, where moderate DLCO reductions reflect pulmonary congestion and inform . Other systemic conditions benefit from PFT for risk stratification and recovery monitoring. In , preoperative PFT identifies restrictive ventilatory defects and rules out alternative hypoventilation causes, aiding planning by highlighting elevated postoperative respiratory risks. Following thoracic surgery, serial PFT monitors recovery, typically showing gradual improvement in lung volumes and spirometric parameters within 6-12 months, depending on resection extent. In these non-respiratory disorders, PFT uniquely emphasizes respiratory muscle testing, such as maximal pressures (detailed in the Tests and Measurements section), over standard alone, as predominantly drives ventilatory limitations rather than intrinsic disease.

Tests and Measurements

Spirometry

is a fundamental pulmonary function test that assesses function by measuring the volume and speed of air that can be inhaled and exhaled during a forced maneuver. The procedure involves the patient inhaling maximally to total capacity (TLC), pausing briefly for no more than 2 seconds, and then exhaling as forcefully and completely as possible into a , typically continuing the exhalation for at least 6 seconds in adults or until no further volume change occurs. This maneuver is repeated at least three times to ensure , with coaching to achieve maximal effort throughout. The test produces a full inspiratory and expiratory flow-volume loop, providing graphical representation of the dynamics. Key parameters derived from spirometry include forced vital capacity (FVC), which is the total volume of air exhaled during the maneuver; forced expiratory volume in 1 second (FEV1), the volume exhaled in the first second; and the FEV1/FVC ratio, which helps evaluate limitation. (PEF), the maximum flow rate achieved during exhalation, offers a quick measure of large airway patency and is often used for monitoring in conditions like . Flow-volume loops visualize the expiratory flow against volume, allowing assessment of effort quality, such as detecting suboptimal blasts or early termination, and identifying patterns suggestive of airway obstruction, like concave scooping in the expiratory limb. These parameters are reported in liters for volumes and liters per second for flows, with ratios as decimals. Spirometers are categorized into volume-displacement types, which directly measure displaced in a chamber or , and flow-sensing types, which detect using transducers like pneumotachographs and integrate signals to derive . Both must comply with international standards, such as ISO 26782:2009, ensuring accuracy within ±2.5% and flow accuracy within ±5% when calibrated with a 3-liter . verification is required daily, with results logged to maintain device reliability. Despite its utility, is effort-dependent, requiring full patient cooperation to yield valid results, and suboptimal performance can lead to underestimation of lung function. It measures dynamic parameters during forced breathing but cannot directly assess static lung volumes like total lung capacity (TLC) or residual volume, necessitating complementary tests for comprehensive evaluation. responsiveness can be assessed as an extension by repeating the maneuver post-administration of a .

Lung Volume Tests

Lung volume tests measure static lung volumes, including total lung capacity (TLC), residual volume (RV), and (FRC), which cannot be directly assessed by alone. These tests are essential for evaluating lung in obstructive diseases or restriction in parenchymal disorders. The primary techniques include body plethysmography and gas dilution methods, each providing insights into lung compartments but differing in accuracy depending on disease severity. Body plethysmography, often considered the gold standard, involves the patient sitting inside a sealed, airtight body box while panting gently against a closed shutter at the . This maneuver creates small changes in (ΔP) and box volume (ΔV), allowing measurement of thoracic gas compression based on (P₁V₁ = P₂V₂). The thoracic gas volume (TGV), which approximates FRC at end-expiration, is calculated as TGV = - (ΔV / ΔP) × P_B, where P_B is barometric corrected to body temperature and saturation (BTPS). From TGV, FRC is derived, and RV is obtained by subtracting expiratory reserve volume (ERV), while TLC is computed as TLC = (VC) + RV. This method accurately measures all compressible gas volumes, including trapped air in poorly ventilated regions, making it reliable in obstructive diseases where occurs. Gas dilution techniques, such as dilution and , measure only the communicating lung volumes by equilibrating a tracer gas with alveolar gas. In dilution, the patient breathes a containing a known concentration of (typically 10%) from a closed circuit starting at FRC. Over several minutes, mixes with gas until equilibrium, and the FRC is calculated from the change in concentration. The derivation begins with the conservation of : initial amount = F_He1 × V_app, where F_He1 is the and V_app is the apparatus . At equilibrium, final concentration F_He2 = (F_He1 × V_app) / (V_app + FRC), solving for FRC yields FRC_He = V_app × (F_He1 / F_He2 - 1), with corrections to BTPS conditions. This method is simple and cost-effective but underestimates volumes in obstructive diseases due to incomplete mixing in areas of gas trapping. Nitrogen washout operates on an open circuit, where the patient inhales 100% oxygen at FRC, washing out from the lungs over multiple breaths until the end-tidal concentration falls below 1/40th of baseline (typically 5-10 minutes). The total exhaled is measured, and FRC is derived as FRC_N2 = [VN2_exhaled + (VN2_tissue contribution)] / F_N2_initial, accounting for from body tissues and dead space, with BTPS correction. Like helium dilution, it excels in normal or restrictive lungs but underestimates FRC in obstruction due to prolonged washout from non-communicating spaces. Comparisons between methods highlight their clinical utility: body plethysmography yields higher FRC values (often 20-50% greater) in obstructive diseases compared to gas dilution techniques, as it captures trapped gas, whereas dilution methods are more precise in homogeneous lungs without . Selection depends on patient characteristics, with plethysmography preferred for accuracy in severe obstruction. In restrictive diseases, these tests confirm reduced TLC and RV, aiding .

Diffusing Capacity

The diffusing capacity of the lung for (DLCO) is a key pulmonary function test that quantifies the lung's ability to transfer gas from inhaled air across the alveolar- membrane into the pulmonary blood. It primarily assesses the integrity of the alveolar surface area and the pulmonary blood volume available for , providing insight into impairments in that are not captured by or lung volume measurements alone. The standard method for measuring DLCO is the single-breath technique, in which the patient inhales a dilute gas containing approximately 0.3% (CO), 10% (or as a tracer gas), 21% oxygen, and the balance , then holds the breath for a fixed period before exhaling. The patient begins by exhaling to residual volume, rapidly inhales the test gas to total lung capacity (achieving at least 85% of in under 4 seconds), holds the breath for 10 ± 2 seconds with minimal effort to avoid straining maneuvers, and then exhales smoothly to residual volume, discarding the initial 0.75–1.0 L of dead-space gas to collect an alveolar sample for analysis. is used because it binds avidly to , minimizing back-pressure from blood, while the tracer gas helps calculate alveolar volume (VA). This uptake of CO during the breath-hold reflects the , with measurements performed using rapid-response gas analyzers for accuracy. The DLCO value is calculated from the single-breath technique using the equation: DLCO=VA×(FICO−FACO)t×PACO‾\text{DLCO} = \frac{V_A \times (F_{I\text{CO}} - F_{A\text{CO}})}{t \times \overline{P_{A\text{CO}}}} where VAV_A is the alveolar volume, FICOF_{I\text{CO}} is the inspired fraction of CO, FACOF_{A\text{CO}} is the alveolar (expired) fraction of CO, tt is the breath-hold time, and PACO‾\overline{P_{A\text{CO}}} is the mean alveolar pressure of CO (adjusted for barometric pressure and water vapor). This formula accounts for the exponential decline in alveolar CO concentration during the breath-hold, approximating the transfer rate; in practice, a logarithmic correction is often applied for precision: DLCO=VAt×(PB−PH2O)×ln⁡(FICOFACO×FATrFITr)\text{DLCO} = \frac{V_A}{t} \times (P_B - P_{H_2O}) \times \ln\left(\frac{F_{I\text{CO}}}{F_{A\text{CO}}} \times \frac{F_{A\text{Tr}}}{F_{I\text{Tr}}}\right), where PBP_B is barometric pressure, PH2OP_{H_2O} is water vapor pressure, and subscript Tr denotes the tracer gas. Alveolar volume VAV_A is derived from the dilution of the inert tracer gas. The test is typically repeated 2–3 times for reproducibility, with values averaged if within 10% variability. Physiologically, DLCO is determined by two main components: the membrane diffusing capacity (DM), which reflects the conductance across the alveolar- , and the blood volume (Vc), which represents the volume of blood available for CO binding in the pulmonary capillaries. These are related through the Roughton-Forster equation, 1/DLCO=1/DM+1/(θ×Vc)1/\text{DLCO} = 1/\text{DM} + 1/(\theta \times V_c), where θ\theta is the specific rate of CO uptake by hemoglobin-laden red blood cells; reductions in either DM (e.g., due to thickening or loss of surface area) or Vc (e.g., due to capillary destruction) lower DLCO. To account for hemoglobin levels affecting CO binding, DLCO is corrected to a standard value (DLCOc) using the formula DLCOc=DLCO×1.7×Hb10.22+Hb\text{DLCOc} = \text{DLCO} \times \frac{1.7 \times \text{Hb}}{10.22 + \text{Hb}} for males (or 9.38+Hb9.38 + \text{Hb} for females), where Hb is in g/dL, normalizing for or . Clinically, DLCO is valuable for detecting intrinsic defects in gas transfer, such as in where low DLCO results from alveolar wall destruction reducing DM and Vc, often with reduced VA due to uneven ventilation-perfusion matching. In contrast, low DLCO due to is typically correctable with adjustment, as VA remains normal, helping differentiate extrinsic from parenchymal causes of impaired . This test integrates briefly with lung volume assessments, as the measured VA approximates total lung capacity when combined with prior volume data.

Additional Specialized Tests

Maximal respiratory pressures evaluate the strength of the respiratory muscles, providing insight into neuromuscular function beyond standard volumetric assessments. Maximal inspiratory pressure (MIP) measures the highest negative pressure generated during a maximal inspiratory effort against an occluded airway, typically performed at residual volume using a flanged mouthpiece with a small leak to prevent oral pressure contributions. Maximal expiratory pressure (MEP) similarly assesses the highest positive pressure during a maximal expiratory effort at total capacity. These tests are particularly useful in diagnosing and monitoring conditions like or , where reduced values indicate inspiratory or expiratory muscle weakness. The American Thoracic Society (ATS) and European Respiratory Society (ERS) recommend multiple efforts (at least 10 for MIP and 5 for MEP) to ensure reproducibility, with the highest consistent value reported. Bronchodilator responsiveness testing assesses the reversibility of airflow obstruction by comparing spirometry results before and after administration of a short-acting , such as albuterol. The patient inhales the bronchodilator via a or , followed by repeat measurements after 10-15 minutes. A positive response is indicated by an increase in forced expiratory volume in one second (FEV1) of at least 12% and 200 mL from baseline, though the 2022 ATS/ERS update refines this to a greater than 10% of the predicted value for more precise classification in and . This test helps differentiate obstructive diseases with reversible components, guiding therapeutic decisions like inhaled initiation. Exercise testing in pulmonary function extends evaluation to dynamic capacity, revealing limitations not apparent in resting tests. The six-minute walk test (6MWT) involves walking as far as possible on a flat, measured course in six minutes, with continuous monitoring of (SpO2) to detect exercise-induced desaturation (typically a drop ≥4%). It serves as a simple, field-based measure of functional exercise tolerance in interstitial diseases or , where distance walked and desaturation patterns inform and needs. Cardiopulmonary exercise testing (CPET) provides a more comprehensive assessment using a cycle ergometer or with incremental workloads, measuring peak oxygen uptake (VO2 max) via analysis to quantify aerobic capacity and identify causes of dyspnea, such as ventilatory or cardiovascular limitations. CPET is indicated for preoperative stratification or unexplained exertional intolerance, offering integrated data on , ventilation, and gas transfer. Arterial blood gas (ABG) analysis complements pulmonary function testing by directly sampling arterial blood to measure pH, partial pressure of oxygen (PaO2), and partial pressure of carbon dioxide (PaCO2), assessing gas exchange efficiency and acid-base status. Performed via radial or femoral artery puncture, it is invasive and reserved for cases where noninvasive oximetry or capnography is insufficient, such as acute respiratory failure or to confirm hypoxemia in chronic lung disease. Unlike routine pulmonary function tests, ABG is not standardized for all patients due to discomfort and risks like hematoma, but it provides critical context for interpreting ventilation-perfusion mismatches. Fractional exhaled (FeNO) offers a noninvasive marker of airway , measured during a single-breath at a constant flow rate of 50 mL/s using a chemiluminescence analyzer. Levels above 50 ppb in adults (or 35 ppb in children) suggest responsive to corticosteroids, aiding diagnosis and management in atopic patients. The ATS recommends FeNO as an adjunct to for guiding therapy, particularly when symptoms are disproportionate to airflow obstruction.

Procedure

Patient Preparation

Proper preparation of patients prior to pulmonary function testing (PFT) is essential to obtain accurate, reproducible results and minimize variability due to external factors. Guidelines recommend that patients withhold certain medications, particularly bronchodilators, depending on the testing purpose; for diagnostic evaluations, short-acting beta-agonists (SABAs) should be withheld for 4-6 hours, long-acting beta-agonists (LABAs) for 24 hours, and long-acting muscarinic antagonists (LAMAs) for 36-48 hours, while for assessing response to therapy, medications are typically not withheld. Patients should avoid , vaping, or using water pipes for at least 1 hour before testing to prevent acute airway irritation that could alter measurements. Additionally, heavy or large meals should be avoided for 2 hours prior, and intoxicants such as alcohol for 8 hours, to reduce discomfort and ensure optimal effort during maneuvers. Patients are advised to wear loose, comfortable clothing that does not restrict chest or abdominal expansion, and to arrive in indoor attire without shoes for accurate anthropometric measurements. Patient education plays a critical role in successful PFT performance, with instructions provided at the time of appointment scheduling and compliance verified upon arrival. Technicians should explain the required breathing maneuvers in simple terms, demonstrate techniques using the equipment, and encourage practice to build confidence and reduce anxiety, which can otherwise lead to suboptimal effort. For special populations, such as children, explanations should be age-appropriate, emphasizing that the test is painless, and patience is key; older children benefit from interactive demonstrations. In elderly or cognitively impaired individuals, operators trained in these groups should use simplified instructions, repeated demonstrations, and reassurance to accommodate potential physical limitations or comprehension challenges. Environmental factors must be controlled to ensure . Testing is typically conducted in the upright position—seated with feet flat on the floor, back supported, and clips applied—unless contraindicated by condition, as this posture optimizes expansion and compared to positioning. The testing room should be quiet, comfortable, and well-ventilated, with ambient maintained between 19°C and 25°C to avoid influencing gas volumes or comfort; and barometric are recorded for each session. Accurate documentation of patient demographics is vital for calculating reference values using equations like those from the Global Lung Function Initiative (GLI). Technicians must record age to one decimal place, standing height in centimeters (measured without shoes, head in Frankfort plane), weight to the nearest 0.5 kg (in indoor clothing), birth sex, and , as these factors significantly affect predicted norms for lung function parameters.

Test Performance and Quality Control

Pulmonary function tests (PFTs) are performed in a controlled setting by trained technicians to ensure accurate and reproducible measurements of function. The process emphasizes patient coaching to achieve maximal effort, with tests typically involving multiple trials until quality standards are met. For , the most common PFT, the procedure consists of four distinct phases: a maximal inspiration to total capacity, a forceful and rapid expiration, a complete expiration lasting at least 6 seconds or until a plateau is reached, and a rapid inspiration back to total capacity. Technicians demonstrate the maneuver to the patient and provide verbal encouragement, such as "blast out as hard and fast as you can" and "keep blowing," while monitoring real-time flow-volume loops on the equipment display to guide adjustments. Between 3 and 8 trials are generally conducted, continuing until two acceptable and reproducible efforts are obtained, to minimize variability and capture the patient's best performance. Quality control in PFTs relies on standardized acceptability and reproducibility criteria established by the American Thoracic Society (ATS) and European Respiratory Society (ERS) to validate data reliability. Acceptability ensures each maneuver meets technical requirements, including no leaks at the mouthpiece, full inspiration and expiration without hesitation, a good start to expiration with back-extrapolated volume ≤5% of the forced or 0.100 L whichever is greater, absence of or closure in the initial phase affecting forced expiratory volume in 1 second (FEV1), and complete exhalation evidenced by an expiratory plateau of no more than 0.025 L in the final second or a forced expiratory time of at least 15 seconds for those with obstruction. Reproducibility requires the two largest values for FEV1 and forced (FVC) to agree within 0.15 L for adults over 6 years, confirming session consistency across trials. These criteria apply similarly to other PFTs, such as lung volume measurements where stable pressure signals indicate no leaks, and tests requiring consistent breath-holding without valve switching artifacts. Trained technicians play a central role in test performance by providing immediate feedback, recognizing and correcting artifacts in real time, and ensuring equipment . They identify issues like submaximal effort through flattened flow-volume curves or via irregular loops, prompting repeat maneuvers with specific to address them, such as emphasizing a tight seal or sustained blow. Software used in PFT devices must adhere to (ISO) 26782 specifications, including volume accuracy within ±2.5% and flow linearity, with daily biological controls and weekly volume linearity checks to validate measurements. Common errors that compromise PFT quality include submaximal effort, leading to underestimated FEV1 and FVC, mouthpiece leaks causing volume loss, premature termination of expiration, and extraneous factors like or hesitation distorting initial flow rates. Post-test review involves grading the entire session on an A-to-F scale, where grade A indicates at least three acceptable maneuvers with the two best FEV1 and FVC within 0.15 L, grade B requires two acceptable and efforts, grade C has two but only one acceptable, grade D shows no despite some acceptability, grade E has no acceptable maneuvers but usable , and grade F denotes no acceptable or values, rendering the test uninterpretable. This grading system, applicable across , lung volumes, and , guides clinical usability, with grades A through C generally considered reliable for interpretation.

Safety Considerations

Risks and Complications

Pulmonary function testing (PFT) is considered a safe procedure overall, with serious adverse events occurring infrequently. A of over 186,000 tests in a tertiary care setting identified patient safety incidents in only 5 per 10,000 routine procedures, primarily consisting of minor cardiopulmonary events such as syncope. The majority of these incidents result in no lasting harm, underscoring the low risk profile when performed under standardized protocols. Common minor risks include and , often resulting from during forced expiratory maneuvers in or other tests. In a of 64,191 PFTs, was reported in approximately 0.44% of cases, typically resolving without intervention. may occur rarely in patients with during , though it can be triggered by deep inhalations or administration. These symptoms are usually transient and self-limiting. Rare complications include , particularly in individuals with pre-existing bullae. Syncope may be associated with the during body plethysmography. In cardiopulmonary exercise testing (CPET), oxygen desaturation or arrhythmias may arise, but major events like or significant hemodynamic instability occur very rarely. To mitigate risks, should be monitored continuously, rescue bronchodilators kept accessible, and testing halted if symptoms such as or severe emerge; adherence to American Thoracic Society guidelines further minimizes these occurrences.

Contraindications

Pulmonary function testing (PFT) involves forced maneuvers that can impose physiological stress, including changes in intrathoracic and cardiovascular , necessitating careful of contraindications to avoid harm. Contraindications are categorized as absolute (where testing should be deferred due to high risk of serious complications) or relative (where testing may proceed if benefits outweigh risks, often after clinical evaluation). These guidelines are informed by standards from organizations such as the American Thoracic Society (ATS) and European Respiratory Society (ERS). Absolute contraindications include conditions where PFT could precipitate life-threatening events. A recent increases the danger of from forced expiration. Active or other transmissible respiratory infections are also absolute to prevent generation and infection spread during testing, with enhanced infection control measures recommended as of 2025. Relative contraindications encompass scenarios where caution is advised, and testing may be modified or postponed. Acute within 1 week poses a cardiovascular due to increased myocardial oxygen demand. Recent , such as extraction, carries a of intraocular changes from Valsalva-like efforts. Severe , defined as systolic exceeding 200 mm Hg or diastolic exceeding 120 mm Hg, heightens the of vascular complications. Inability to follow instructions, often due to or acute distress, can lead to invalid results and unnecessary strain. Other relative factors include of unknown origin, , thoracic or abdominal aneurysms, recent major surgery (e.g., thoracic or abdominal), and acute illnesses like or chest infections that impair performance. Special considerations apply in certain populations. is generally not contraindicated for PFT, as it represents a normal physiological state without inherent risks from the tests, though it should be avoided in high-risk cases such as complicated pregnancies or when alternative assessments suffice. Abdominal aortic aneurysms warrant relative caution due to potential rupture from pressure fluctuations. When PFT is contraindicated, alternatives such as chest imaging (e.g., CT scans) or non-invasive monitoring like can provide supportive diagnostic information without the associated risks. In some cases, less demanding techniques like impulse oscillometry may be considered as substitutes.

Interpretation

Normal Reference Values

Normal reference values for pulmonary function tests (PFTs) are established through prediction equations derived from large cohorts of healthy individuals, ensuring adjustments for key demographic factors to reflect physiological norms accurately. The Global Lung Function Initiative () Global 2023 race-neutral equations serve as the current widely adopted global standard for spirometry, providing continuous reference values for forced expiratory volume in 1 second (FEV1), forced vital capacity (), and their ratio across ages 3 to 95 years, incorporating adjustments for age, sex, and height without ethnicity factors to promote equity in interpretation. These equations define the lower limit of normal (LLN) as the 5th percentile of the predicted distribution (z-score of -1.645), below which values are considered abnormal. The previous GLI-2012 equations included ethnicity adjustments but have been superseded by the race-neutral GLI Global model as recommended by the American Thoracic Society (ATS) and European Respiratory Society (ERS) as of 2023. Key normal ranges for common PFT parameters are expressed relative to predicted values to account for individual variability. For , FEV1 typically falls between 80% and 120% of predicted, while the exceeds 70-75% (or remains within 5% of the age-specific predicted ratio). (DLCO) is generally 75-125% of predicted, reflecting efficient gas transfer in healthy s. These ranges establish the baseline for assessing lung function, with values outside them prompting further evaluation. Sources of variability in reference values include environmental and lifestyle factors that can alter norms even in healthy populations. , for instance, reduces FEV1 norms by 10-20% compared to non-smokers due to airway and accelerated lung function decline, necessitating consideration in prediction models. Altitude influences measures like DLCO, as lower barometric pressure reduces inspired oxygen , potentially increasing measured DLCO by 10% or more at high elevations unless corrected. For precise interpretation, especially in or diverse populations where traditional percent-predicted values may skew due to non-normal distributions, z-scores are preferred over percent predicted. Z-scores standardize results by expressing deviation from the mean in standard deviation units (with LLN at -1.645), providing a more robust metric for cross-group comparisons and longitudinal tracking as recommended by international guidelines.

Disease-Specific Patterns

Pulmonary function tests (PFTs) reveal characteristic patterns in obstructive lung diseases, primarily through and lung volume measurements. In (COPD), airflow limitation is indicated by a reduced below 70% post-, reflecting persistent airway obstruction. Lung volumes show with increased residual volume (RV) and an elevated RV/total lung capacity (TLC) ratio often exceeding 40%, due to . (DLCO) is typically reduced in the emphysema-predominant subtype of COPD, signifying impaired from alveolar destruction. In contrast, presents an obstructive pattern with a low that demonstrates reversibility, defined as an increase of at least 12% and 200 mL in FEV1 following administration. Restrictive patterns on PFTs are characterized by reduced lung volumes with a preserved or elevated . In interstitial lung diseases (ILDs), such as , total lung capacity (TLC) is decreased below 80% of predicted values, alongside a low DLCO due to thickened alveolar-capillary membranes impairing . The remains normal, distinguishing parenchymal restriction from obstruction. In , a mild restrictive defect emerges primarily from reduced expiratory reserve volume (ERV), often dropping significantly as rises, while TLC may be mildly affected and DLCO remains normal. Unique or mixed patterns highlight specific pathologies beyond pure obstruction or restriction. Neuromuscular disorders, like , typically show normal or mildly reduced lung volumes with a normal and preserved DLCO, but reveal respiratory through low maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values, often below 60 cmH2O and 80 cmH2O, respectively. In pulmonary vascular diseases, such as , and lung volumes are normal, but DLCO is markedly reduced, reflecting vascular obstruction without parenchymal involvement. Severity grading in COPD relies on post-bronchodilator FEV1 as a percentage of predicted values, per Global Initiative for Chronic Obstructive Lung Disease () criteria: mild (GOLD 1, ≥80%), moderate ( 2, 50–79%), severe (GOLD 3, 30–49%), and very severe ( 4, <30%). These stages correlate with symptom burden and prognosis, though they are now supplemented by symptom and exacerbation assessments in clinical management. For restrictive diseases, severity is similarly gauged by the degree of TLC or FEV1 reduction relative to predicted norms, with greater decrements indicating worse impairment.

Clinical Applications

Diagnostic Uses

Pulmonary function testing (PFT) serves as a cornerstone in the diagnostic evaluation of respiratory symptoms by providing quantifiable data on lung mechanics, volumes, and gas exchange, enabling clinicians to confirm or exclude specific pathologies. In the context of dyspnea, a common presenting symptom, PFTs facilitate differential diagnosis by differentiating intrinsic lung diseases from extrapulmonary causes such as cardiac dysfunction. Abnormal results, including obstructive patterns with reduced forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio below 0.7 or restrictive patterns with decreased total lung capacity (TLC), point to primary pulmonary involvement, whereas normal PFTs support a cardiac etiology like congestive heart failure, where lung function remains preserved despite breathlessness. This distinction is particularly valuable when integrated with clinical history and imaging, as supported by evaluations emphasizing PFTs' role in ruling out lung disease in cardiac dyspnea cases. For confirming specific diagnoses, PFTs offer targeted insights aligned with established guidelines. is recommended by the Global Initiative for Asthma (GINA) to verify through evidence of variable expiratory airflow limitation, typically demonstrated by a bronchodilator response showing an increase in FEV1 of at least 12% and 200 mL from baseline after administration of a short-acting beta-agonist. This reversibility distinguishes from fixed obstructions and is assessed in adults and children over 6 years, with repeat testing during symptoms if initial results are inconclusive. Similarly, (DLCO) is crucial for diagnosis within (COPD), where reduced values indicate alveolar destruction and impaired gas transfer, helping differentiate it from other obstructive conditions like chronic bronchitis where DLCO may be normal. Beyond acute diagnostics, PFTs quantify impairment for assessments under frameworks like the U.S. (SSA) criteria, which rely on post-bronchodilator to evaluate severity in respiratory listings (e.g., 3.02 for chronic respiratory disorders). FEV1 values are pivotal: FEV1 equal to or less than the values specified in Table I of SSA listing 3.02A based on height, gender, and age (e.g., for height 65 inches and age 20+, ≤1.35 L for females and ≤1.50 L for males) meets listing-level impairment for obstructive diseases, requiring documentation of stable conditions and satisfactory test efforts to ensure validity for or legal claims. PFTs also enable proactive screening in high-risk populations to detect subclinical disease. For occupational exposures, such as among workers, the (OSHA) mandates annual surveillance including to measure FVC and FEV1, identifying early restrictive or obstructive changes from pleural or before radiographic evidence emerges. In genetic screening for (AAT) deficiency, PFTs are recommended at COPD diagnosis to uncover premature in nonsmokers or those with family history, with abnormal airflow limitation prompting confirmatory AAT level and testing; integrating direct AAT screening (e.g., ) in PFT laboratories has been shown to boost detection rates up to 50-fold compared to physician referrals.

Monitoring and Prognosis

Pulmonary function testing plays a key role in monitoring disease progression and assessing in chronic respiratory conditions through serial measurements that track changes over time. In (COPD), may be repeated periodically, with frequency determined by clinical judgment, to evaluate the rate of forced expiratory volume in 1 second (FEV1) decline as a marker of treatment response and disease trajectory. As per the 2025 GOLD report, monitoring should also consider comorbidities like and . In healthy nonsmokers, FEV1 typically declines by 20-30 mL per year with advancing age, but this rate accelerates in smokers and COPD patients, often exceeding 50 mL per year, highlighting the impact of exposure and the potential benefits of or in slowing progression. For (IPF), serial (DLCO) assessments are essential for tracking progression, as a decline to below 40% of predicted value strongly predicts poor survival outcomes, with median survival often reduced to less than 2 years in such cases. This threshold serves as a critical indicator for considering interventions like referral, emphasizing DLCO's role in prognostic stratification beyond baseline patterns. In surgical planning for lung resection, such as , preoperative pulmonary function tests predict postoperative FEV1, with values exceeding 40% of predicted generally indicating acceptable risk for complications and supporting proceeding with surgery. This quantitative estimation, often derived from quantitative ventilation-perfusion scans or segmental counting methods, helps balance oncologic benefits against postoperative pulmonary morbidity. Prognostic indices like the BODE index integrate pulmonary function data with clinical measures to forecast mortality risk in COPD. The BODE index combines , FEV1 percent predicted, dyspnea (via Modified Medical Research Council scale), and exercise capacity (6-minute walk test distance), yielding a score from 0 to 10 where higher values correlate with elevated all-cause and respiratory mortality over 4-5 years of follow-up. This multidimensional tool outperforms FEV1 alone in predicting outcomes and guides personalized management strategies.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK482339/
  2. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/pulmonary-function-tests
  3. https://my.clevelandclinic.org/health/diagnostics/17966-pulmonary-function-testing
  4. https://www.thoracic.org/patients/patient-resources/resources/pulmonary-function-tests.pdf
  5. https://www.atsjournals.org/doi/10.1164/rccm.202302-0310ST
  6. https://www.thoracic.org/statements/resources/pft/PFT1.pdf
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC9488829/
  8. https://www.embs.org/pulse/articles/spirometry-a-historical-gallery/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC4303379/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC522260/
  11. https://publications.ersnet.org/content/erj/26/1/1
  12. https://www.thoracic.org/statements/resources/pft/pft5.pdf
  13. https://www.atsjournals.org/doi/10.1164/rccm.201908-1590ST
  14. https://www.thoracic.org/statements/resources/pft/DLCO.pdf
  15. https://publications.ersnet.org/content/erj/60/1/2101499
  16. https://www.jonesmedical.com/brief-history-spirometer/
  17. https://www.sciencedirect.com/science/article/abs/pii/0010480983900216
  18. https://www.liebertpub.com/doi/10.4187/respcare.01585
  19. https://www.atsjournals.org/doi/10.1164/rccm.202202-0399ST
  20. https://www.ncbi.nlm.nih.gov/books/NBK560880/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4283874/
  22. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201301-017ST
  23. https://www.ncbi.nlm.nih.gov/books/NBK555902/
  24. https://goldcopd.org/2025-report/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC6025604/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC10114271/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC11561952/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC9536996/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7249789/
  30. https://www.ncbi.nlm.nih.gov/books/NBK542216/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC9309725/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC6053085/
  33. https://www.iso.org/standard/43792.html
  34. https://www.thoracic.org/statements/resources/pft/pft3.pdf
  35. https://doi.org/10.1183/13993003.00016-2016
  36. https://www.atsjournals.org/doi/10.1164/rccm.166.4.518
  37. https://www.atsjournals.org/doi/10.1164/ajrccm.166.1.at1102
  38. https://www.thoracic.org/professionals/clinical-resources/critical-care/clinical-education/abgs.php
  39. https://www.atsjournals.org/doi/full/10.1164/rccm.202109-2093ST
  40. https://www.thoracic.org/patients/patient-resources/resources/pulmonary-function-testing-children.pdf
  41. https://channel.ersnet.org/media-113711-spirometry-in-children-and-elderly
  42. https://publications.ersnet.org/content/breathe/8/3/232
  43. https://www.atsjournals.org/doi/10.1164/rccm.201710-1981ST
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC6925499/
  45. https://thorax.bmj.com/content/66/8/714
  46. https://bmjopenrespres.bmj.com/content/7/1/e000575
  47. https://www.news-medical.net/health/Spirometry-Indications-and-Contraindications.aspx
  48. https://emedicine.medscape.com/article/303239-overview
  49. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805470
  50. https://www.ersnet.org/science-and-research/ongoing-clinical-research-collaborations/the-global-lung-function-initiative/gli-tools/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3786581/
  52. https://www.aafp.org/pubs/afp/issues/2004/0301/p1107.html
  53. https://www.lung.org/getmedia/d53c0e59-f3ab-435a-bcaa-a6a195b6b565/Spirometry-quick-glance-guide.pdf
  54. https://www.ncbi.nlm.nih.gov/books/NBK556149/
  55. https://biomedpharmajournal.org/vol11no2/effects-of-cigarette-smoking-and-age-on-pulmonary-function-tests-in-40-years-old-adults-in-jordan/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC4717181/
  57. https://www.thoracic.org/statements/resources/pft/standardized-pulmonary-function-report.pdf
  58. https://goldcopd.org/wp-content/uploads/2024/11/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC4575935/
  60. https://ginasthma.org/wp-content/uploads/2024/12/GINA-Summary-Guide-2024-WEB-WMS.pdf
  61. https://publications.ersnet.org/content/breathe/19/1/220263
  62. https://www.sciencedirect.com/science/article/abs/pii/S0960896620301590
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC5247680/
  64. https://www.aafp.org/pubs/afp/issues/1998/0215/p711.html
  65. https://ginasthma.org/wp-content/uploads/2025/05/GINA-2025_tracked-for-archive-WMSA.pdf
  66. https://www.ssa.gov/disability/professionals/pfs-pub055.htm
  67. https://www.osha.gov/laws-regs/regulations/standardnumber/1926/1926.1101AppI
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC3164601/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC8237974/
  70. https://goldcopd.org/2025-gold-report/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC6597635/
  72. https://www.bmj.com/content/1/6077/1645
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC6024649/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC8350467/
  75. https://pubmed.ncbi.nlm.nih.gov/14999112/
Add your contribution
Related Hubs
User Avatar
No comments yet.